My point is that all of this should be explained instead of speculated. I would also want to know if there was any efficacy at all in the "iSONEP only" arm like we saw in Phase I, who benefited and how much. I can't imagine why that information would be held. That was the crux of the study.
Gary said to me in an e-mail that since the DSMB did not tell them to stop the study, they must have seen some patients obtaining some benefit. He obviously threw a Safe Harbor saying that didn't necessarily mean there were enough patients benefiting to meet the study endpoints. That is however a very interesting point given the unadulterated "fail" we were given. They definitely owe us a call.